The effect of prophylactic medications on TMS for migraine aura

Headache

Volumn 50, Issue 10, 2010, Pages 1630-1633

  Almaraz, Amy C ^a   Dilli, Esma ^b   Dodick, David W ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

aura; migraine; transcranial magnetic stimulation

Indexed keywords

NORTRIPTYLINE; PROPRANOLOL; TOPIRAMATE; VALPROATE SEMISODIUM;

CLINICAL TRIAL; DISEASE SEVERITY; HUMAN; MIGRAINE WITH AURA; NOCICEPTION; PAIN ASSESSMENT; PAIN THRESHOLD; PATIENT SAFETY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SHAM PROCEDURE; SPREADING CORTICAL DEPRESSION; SYMPTOM; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; COMBINED MODALITY THERAPY; CORTICAL SPREADING DEPRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE WITH AURA; PAIN MEASUREMENT; TRANSCRANIAL MAGNETIC STIMULATION; YOUNG ADULT;

EID: 78649250681     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2010.01787.x     Document Type: Review

References (14)

1. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF, AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007; 68: 343-349.
2. Stovner L, Hagen K, Jensen R, et al. The global burden of headache: A documentation of headache prevalence and disability worldwide. Cephalalgia. 2007; 27: 193-210.
3. Goadsby PJ, Ferrari MD, Lipton RB,. Migraine-current understanding and treatment. NEJM. 2002; 364: 257-270.
4. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ,. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet. 2001; 358: 1668-1675.
5. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB,. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002; 22: 633-658.
6. st Annual Meeting of the Academy of Neurology; 2009 Apr 25; Seattle, WA.
7. Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA,. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med. 2002; 8: 136-142.
8. Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz MA,. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol. 2006; 59: 652-661.
9. th Annual Scientific Meeting of the American Headache Society; 2008 June 26; Boston, MA.
10. Anand S, Hotson J,. Transcranial magnetic stimulation: Neurophysiological applications and safety. Brain Cogn. 2002; 50: 366-386.
11. Clarke BM, Upton AR, Kamath MV, Al-Harbi T, Castellanos CM,. Transcranial magnetic stimulation for migraine: Clinical effects. J Headache Pain. 2006; 7: 341-346.
12. th Annual Scientific Meeting of the American Headache Society; 2006 June 23; Los Angeles, CA.
13. Wassermann E,. Risk and safety of repetitive transcranial magnetic stimulation: Report and suggested guidelines from the International Workshop on the Safety of Repetitive Transcranial Magnetic Stimulation, June 5-7, 1996. Electroencephalogra. Clin Neurophysiol. 1998; 108: 1-16.
14. Committee on the Possible Effects of Electromagnetic Fields on Biologic Systems, National Research Council. Possible Health Effects of Exposure to Residential Electric and Magnetic Fields. Washington, DC: National Academies Press; 1997: 12.